Scientific Vita
Publi­cations
Con­tact

Prof. Dr.

Mathias Heikenwälder

Academic Education and University Degrees
2009
Habilitation in Experimental Pathology, Medical Faculty, University Hospital Zürich, Switzerland, mentor Prof. Dr. Holger Moch
2004
Graduation as Dr. sc. nat. at the University of Zürich, Switzerland with a Ph.D
2001
Ph.D. thesis, Institute of Neuropathology, University Hospital Zürich (USZ), Switzerland (Grade: summa cum laude); supervised by Prof. Dr. Adriano Aguzzi
1999
Diploma thesis with the group of Prof. Dr. Martin Zenke, Max-Delbrück center for Molecular Medicine (MDC), Berlin, Germany
1994 - 1999
Studies of Microbiology and Genetics at the University of Vienna, Austria, the Max-Perutz laboratories, Vienna, and the Institute of Molecular Pathology (IMP), Vienna, Austria.

Employment
Since 2020
Group leader at the Dep. of Infectious Diseases, Molecular Virology
Since 2015
Research group leader Institute of Molecular Immunology and Experimental Oncology
Since 2015
W3-Professur „Infection and Cancer“, German Cancer Research Center Heidelberg and Medical Faculty, Heidelberg University, Germany
2012
W2-Professor, TU München and Research Associate at the University Hospital of Zürich, Clinical Pathology; Munich, Germany
2010
Helmholtz Young Investigator, Helmholtz-Zentrum München (HMGU), Germany
2010
Sponsor and leading investigator of a clinical trial at the clinical trial Center Zürich (CTC), University Hospital Zürich, Switzerland to treat HCV-genotype 1 infected patients, group leader at the Dep. of Pathology USZ.
2007
Prof. Dr. Max-Cloëtta fellow and independent group leader at the Department of Pathology and start as a principal investigator (PI), University of Zürich, Switzerland
2006
Staff scientist and lecturer in the Department of Pathology, Institute of Neuropathology, University of Zürich, Switzerland
2004
Postdoctoral fellow at the Institute of Neuropathology, Pathology Department, University Hospital Zürich (USZ), Switzerland.
Namineni S, O‘Connor T*, Faure-Dupuy S*, Johansen P, …, Protzer U, Wohlleber D, Holzmann B, Binder M, … Lucifora J, Kalinke U, Knolle PA, Heikenwalder M. 2019. A dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control. The Journal of Hepatology. 01/12 in press.
Malehmir M, Pfister D, Gallage S, …, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A. Heikenwalder M. 2019. Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer. Nature Medicine. 25(4):641-655.
Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M. 2018. Single cell polarity in liquid phase facilitates tumour metastasis. Nature Communications. 9(1):887.
Yuan D, Huang S, …, Wohlleber D, Jörs S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle PA, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D°, Heikenwalder M°. 2017. Kupffer-cell derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell. 31(6):771-789.
Mejías-Luque R, Zöller J, Anderl F, Loew-Gil E, Vieth M, Adler T, Engler DB, Urban S, Browning JL, Müller A, Gerhard M, Heikenwalder M. 2016. Lymphotoxin β receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner. Gut. 66(8):1369-1381.
Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle PA, Weber A°, Heikenwalder M°. 2014. Metabolic activation of intrahepatic CD8+ T-cells and NKT-cells causes nonalcoholic steatohepatitis and hepatocellular carcinoma via cross-talk with hepatocytes. Cancer Cell. 26:549-564.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M°, Potzer U°. 2014. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 343:1221-1228.
Seleznik GM, Reding T, Romrig F, Saito Y, Mildner A, Segerer S, Sun LK, Regenass S, Lech M, Anders HJ, McHugh D, Kumagi T, Hiasa Y, Lackner C, Haybaeck J, Angst E, Perren A, Balmer ML, Slack E, MacPherson A, Manz MG, Weber A, Browning JL, Arkan MC, Rülicke T, Aguzzi A, Prinz M, Graf R, Heikenwalder M. 2012. Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis.Gastroenterology. 143(5):1361-1374.
Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. 2012. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 22:91-105.
Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. 2009. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 16:295-308.
° co-last, co-correspondance
Address
Department of Infectious Diseases, Molecular Virology
Medical Faculty Heidelberg University
Im Neuenheimer Feld 344
69120 Heidelberg
eMail
mathias.heikenwaelder@med.uni-heidelberg.de